Moderna, AbbVie, Danaher, Regeneron Pharmaceuticals, and Natera are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that use biological science to develop products or services, such as medicines, vaccines, and diagnostic tests. For investors, they can offer growth potential but often carry higher risk because a company’s prospects may depend on uncertain research results, regulatory approval, and funding. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Shares of MRNA traded down $6.32 during trading on Wednesday, reaching $244.51. The company's stock had a trading volume of 2,865,872 shares, compared to its average volume of 12,598,158. The company has a quick ratio of 3.47, a current ratio of 3.62 and a debt-to-equity ratio of 0.52. The company has a market cap of $98.94 billion, a price-to-earnings ratio of -34.37 and a beta of 1.16. Moderna has a twelve month low of $22.28 and a twelve month high of $280.80. The company has a fifty day moving average of $196.68 and a two-hundred day moving average of $93.60.
Read Our Latest Research Report on MRNA
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
ABBV traded down $3.19 on Wednesday, hitting $290.70. 952,468 shares of the company's stock were exchanged, compared to its average volume of 6,308,325. The stock has a fifty day moving average of $273.45 and a two-hundred day moving average of $239.80. AbbVie has a twelve month low of $190.75 and a twelve month high of $302.93. The firm has a market cap of $513.85 billion, a PE ratio of 50.04, a P/E/G ratio of 1.33 and a beta of 0.20.
Read Our Latest Research Report on ABBV
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
DHR stock traded up $1.29 during mid-day trading on Wednesday, reaching $237.40. The company had a trading volume of 1,048,523 shares, compared to its average volume of 4,431,774. The stock's 50-day simple moving average is $221.10 and its two-hundred day simple moving average is $201.55. Danaher has a one year low of $160.93 and a one year high of $242.80. The stock has a market capitalization of $167.02 billion, a P/E ratio of 38.83, a P/E/G ratio of 2.95 and a beta of 0.76. The company has a quick ratio of 1.29, a current ratio of 1.63 and a debt-to-equity ratio of 0.45.
Read Our Latest Research Report on DHR
Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
REGN traded up $4.07 during trading hours on Wednesday, hitting $920.13. The company's stock had a trading volume of 242,594 shares, compared to its average volume of 830,868. The company has a 50-day simple moving average of $809.24 and a 200 day simple moving average of $744.46. The company has a current ratio of 3.35, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $95.19 billion, a PE ratio of 20.29, a PEG ratio of 1.22 and a beta of 0.10. Regeneron Pharmaceuticals has a fifty-two week low of $591.52 and a fifty-two week high of $991.73.
Read Our Latest Research Report on REGN
Natera (NTRA)
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Shares of NASDAQ:NTRA traded up $8.37 on Wednesday, hitting $320.35. The company's stock had a trading volume of 569,419 shares, compared to its average volume of 1,461,210. The stock's 50-day moving average is $379.93 and its two-hundred day moving average is $270.42. The company has a market capitalization of $46.45 billion, a price-to-earnings ratio of -280.26 and a beta of 1.55. Natera has a 12 month low of $181.00 and a 12 month high of $437.41.
Read Our Latest Research Report on NTRA
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
